The antibacterial properties of MCT1 and MCT4 inhibitors (i.e., Su3118, VB124 + AZD3965) endow them with newfound significance, particularly crucial in the fact of the threat of antibiotic failures in treating bacterial infections. Here, SLC16A1 is linked to bacterial infectious disease.